Bharat Biotech, the maker of coronavirus disease vaccine Covaxin, is expected to start paediatric trials from June, the company’s Business Development and International Advocacy Head Dr Raches Ella on Sunday.
“We focused on developing the product last year. Now our focus is on ramping up our manufacturing capacity. Kids vaccine trials of Bharath Biotech may get the license in the third quarter of this year,” Dr Ella said during a virtual conversation with members of FICCI Ladies Organisation (FLO), Hyderabad.
Responding to a question from one of the participants, Dr Ella said that Bharat Biotech will be ramping up the manufacturing capacity of Covaxin to 700 million doses by the end of this year.
“We are happy to have the full support of the government because of which we are able to stand where we are today in this journey. The vaccine is co-developed by us and ICMR. The government placed an advanced purchase order of ₹1,500 crore. This will help us to increase our risk appetite. That is why we are expanding to Bangalore and Gujarat,” he added.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…